Terns Pharmaceuticals (TERN) Expected to Announce Earnings on Tuesday

Terns Pharmaceuticals (NASDAQ:TERN) is expected to post its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Terns Pharmaceuticals to post earnings of ($0.30) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Terns Pharmaceuticals Stock Up 2.4%

Shares of TERN stock opened at $49.61 on Tuesday. The firm has a market cap of $5.15 billion, a price-to-earnings ratio of -48.17 and a beta of -0.31. Terns Pharmaceuticals has a 12 month low of $1.87 and a 12 month high of $50.89. The stock has a 50-day moving average price of $40.01 and a 200 day moving average price of $28.10.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on TERN shares. Barclays raised their price target on Terns Pharmaceuticals from $36.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. BMO Capital Markets upped their price objective on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. HC Wainwright raised their target price on Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Leerink Partners began coverage on Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price for the company. Finally, UBS Group raised Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $58.11.

Insiders Place Their Bets

In related news, insider Emil Kuriakose sold 1,155 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35. Following the sale, the insider owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the transaction, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 170,409 shares of company stock valued at $6,563,769. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Terns Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Vestal Point Capital LP bought a new position in shares of Terns Pharmaceuticals during the 4th quarter valued at about $181,800,000. Janus Henderson Group PLC bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $136,496,000. Nearwater Capital Markets Ltd acquired a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $68,874,000. Adage Capital Partners GP L.L.C. raised its holdings in Terns Pharmaceuticals by 40.9% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company’s stock worth $224,220,000 after buying an additional 1,611,000 shares during the period. Finally, Ikarian Capital LLC lifted its stake in Terns Pharmaceuticals by 872.2% in the fourth quarter. Ikarian Capital LLC now owns 1,596,378 shares of the company’s stock valued at $64,494,000 after buying an additional 1,432,176 shares in the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.